Table 3 Registered clinical trials of MSC-based therapy in kidney transplantation according to ClinicalTrials.gov

NCT03478215

To investigate the safety and effectiveness of dose-escalation MSCs infusion compared to saline-only infusion in kidney transplantation

Phase 2

Recruiting

NCT02565459

To test MSCs as a strategy to induce tolerance in kidney transplant recipients

Phase 1

Recruiting

NCT02057965

To test the effectiveness of MSCs in combination with everolimus in facilitating tacrolimus withdrawal

Phase 2

Recruiting

NCT02492308

To determine the efficacy of autologous SVF derived MSCs in reduction of posttransplant immunosuppressants

Phase 1 and 2

Recruiting

NCT02409940

To evaluate the effect of allogeneic or autologous MSCs on immune cell response in kidney transplantation

Phase 1

Active but not recruiting

NCT02490020

To clarify the key role of MSCs to reduce AR and DGF after renal transplantation

Phase 1

Enrolling by invitation

NCT02561767

To determine the efficacy and safety of allogeneic MSCs in kidney transplantation

Phase 1 and 2

Not yet recruiting

NCT02563340

To investigate the efficacy and safety of allogeneic MSCs on chronic AMR after kidney transplantation

Phase 1 and 2

Not yet recruiting

NCT02563366

To investigate whether allogeneic MSCs can promote function recovery in patients with poor early graft function after kidney transplantation

Phase 1 and 2

Not yet recruiting

NCT03585855

To find out the effectiveness of MSCs in combination with standard therapy against AMR

Not applicable

Terminated (safety reason)

NCT00752479

To define the safety and biological/mechanistic effect of MSCs in living-related kidney transplant recipients

Phase 1 and 2

Terminated (necessity of major revision of the protocol)